The status of the many people in occupations exposing them to bovine brucellosis with high serological titres of brucella antibody is uncertain (Annotation, 1966) . They may either suffer from chronic, subclinical or latent brucellosis or have an acquired immunity with persistent antibody levels (Coghlan and Weir, 1967; Henderson, 1967) . Concern has also been expressed at the large proportion of such a group which has symptoms as well as positive serological tests (Kerr, Coghlan, Payne, and Robertson, 1966a) .
It would be useful to have a method of treatment that would eliminate infection in those in whom it persisted but would not harm those who were immune. As there is at present no way of distinguishing between the subclinical and immune groups, both might have to be treated.
The opportunity to investigate the treatment of an occupationally exposed group with high serological 67 4 titres of brucella antibody arose during the course of a survey into the serological incidence of brucellosis in Northern Ireland (McDevitt, 1968) . The resurgence of interest in brucellosis, allied to a belief in the validity of the anti-human globulin (Coombs) test and the complement-fixation test as reliable diagnostic tools, resulted in concern amongst the veterinary surgeons as to whether they might be suffering from the disease. Some had been notified of positive serology at various veterinary conferences; others had attended their medical practitioners with vague ailments and, after serological tests, been diagnosed as suffering from brucellosis. Many expressed the desire, if their serological tests were positive, to have a course of treatment, irrespective of whether they complained of symptoms or not.
It was decided, therefore, to try the effectiveness of ampicillin as a therapeutic agent in these patients. (Kerr, 1967 Alton and Jones (1967) at serum dilutions from 1/10 to 1/5120. The antigen used was an agglutinable suspension of Br. abortus strain 99, standardized to give 50% agglutination with a 1/500 dilution of International Standard Serum.
Anti-human globulin (Coombs) test The method of Wilson and Merrifield (1951) , as modified by Kerr, Coghlan, Payne, and Robertson (1966b) , was used. The antigen was the same as described above. Anti-human precipitating rabbit serum (Burroughs-Wellcome) was used at its optimal dilution.
Complement-fixation test This test was performed as described by Bradstreet and Taylor (1962) , using a fourvolume test (unit volume 0-1 ml.) in W.H.O. plastic plates. The short fixation method only was used with 2-0 M.H.D. of complement and the optimal dilution of antigen (heat-killed Br. abortus strain 99) as determined by a chessboard titiation. In each series of tests a known control serum was included.
Statistical methods
In comparison between the various groups, the x2 test was used when the numbers involved were big enough. When numbers were too small for valid application of x2, the exact probability test was used. In the latter test, double tail probability is quoted.
Results
Of the 99 people to whom treatment was offered, 84 initially indicated their desire to take part in the trial. Fifteen of these failed to submit a pre-treatment blood sample and were withdrawn, as was one veterinary surgeon who reported previous penicillin sensitivity.
Thus 68 people finally participated in the trial. They comprised 45 Table 1 . One other patient, who was taking the placebo, after completing the course, reported ill with symptoms ascribed to chronic brucellosis and was withdrawn for immediate treatment with tetracycline and streptomycin; four people failed to complete the treatment coursethree, who were on the placebo through inattention, and one from side-effects due to ampicillin. Nine people failed to send in either their post-treatment questionnaire or their post-treatment blood sample or both: five of these were taking ampicillin and four placebo. Of the 54 people completing the trial, 24 had taken ampicillin and 30 the placebo. There was no significant difference between the titres of the two pre-treatment sera of the ampicillin and placebo groups measured by the Coombs test (p = 0-68) or the complement-fixation test (p = 0-13). Thus any statistically significant titre variations observed during treatment would not be expected to be due to normal fluctuation. However, there was no significant difference between the two groups in the variation of the Coombs titre (p = 0-55) or complement-fixation titre (p = 0-68) between the immediate pre-treatment and the post-treatment sera (Table 3) . (Spink, 1960; Rizzo-Naudi, Griscti-Soler, and Ganado, 1967) , but it has also been recommended that streptomycin be added in severe cases (Spink, 1960) or in chronic brucellosis (British Medical Journal, 1967) . Several authors do not feel that this addition augments the possibility of improvement (Farid, Miale, Omar, and Van Peenen, 1961;  Rizzo-Naudi et al., 1967), although Richardson and Holt (1962) have shown experimentally that streptomycin acts synergistically with other antibiotics on intracellular Br. abortus in vitro.
One of the problems of brucellosis is the intracellular localization of the brucella organisms in the tissues of the host (Spink, 1952) . In these sites the bacteria are probably protected against both drugs and humoral antibodies (Magoffin and Spink, 1951; Shaffer, Kucera, and Spink, 1953) , and there is experimental evidence that this protection occurs against long-term tetracycline therapy (Spink and Bradley, 1960) .
Ampicillin is potentially useful in the treatment of brucellosis. Its spectrum of activity is similar to that of tetracycline (Trafford, Maclaren, Lillicrap, Barnes, Houston, and Knox, 1962) ; it is bactericidal , whereas tetracycline is bacteriostatic. Ampicillin is active against brucellae in vitro (Agius and Mifsud, 1962; Robinson, 1966) . Large doses can be taken to ensure high concentrations (Knudsen, Rolinson, and Stevens, 1961) and it has some powers of intracellular penetration (Postgraduate Medical Journal, 1964) . Apart from producing skin rashes and some gastro-intestinal upset, it is safe even in high dosage (Stratford, 1964) .
Unfortunately, there was no evidence from this trial that ampicillin had any beneficial effect either subjectively or serologically.
No comprehensive study of the effectiveness of ampicillin in brucellosis had been made previously. Farid, Bassily, and Omar (1964) reported two patients with Br. melitensis septicaemia who had failed to respond to ampicillin, 750 mg. four times a day. The only other reported instance of its use was by Lutton (1966) in a rather bizarre case said to be chronic brucellosis. The patient recovered but had also received streptomycin, tetracycline, sulphonamide, nystatin, and prednisone. Thus individual drug evaluation was impossible.
Since this trial began, Farid, Bassily, and Omar (1967) There would seem to be a need for further work to investigate the value of other therapies in these patients. Until this has been done a cautious and critical approach to both the diagnosis and treatment of brucellosis will be necessary. These studies were supported by generous grants from the research funds of the Queen's University of Belfast and the Northern Ireland Hospitals Authority.
